(VIANEWS) – United Therapeutics Corporation (UTHR), AMETEK (AME), ICON plc (ICLR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. United Therapeutics Corporation (UTHR)
15.6% sales growth and 20.08% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $21.12.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 13.09. Meaning, the purchaser of the share is investing $13.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.08%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 33.7%, now sitting on 2.5B for the twelve trailing months.
2. AMETEK (AME)
12.9% sales growth and 15.77% return on equity
AMETEK, Inc. manufactures and sells electronic instruments and electromechanical devices in the North America, Europe, Asia, and South America, and internationally. The company's EIG segment offers advanced instruments for the process, aerospace, power, and industrial markets; process and analytical instruments for the oil and gas, petrochemical, pharmaceutical, semiconductor, automation, and food and beverage industries; instruments to the laboratory equipment, ultra-precision manufacturing, medical, and test and measurement markets; power quality monitoring and c devices, uninterruptible power supplies, programmable power and electromagnetic compatibility test equipment, and sensors for gas turbines and dashboard instruments; heavy trucks, instrumentation, and controls for the food and beverage industries; and aircraft and engine sensors, power supplies, embedded computing, monitoring, fuel and fluid measurement, and data acquisition systems for aerospace and defense industry. Its EMG segment offers engineered medical components and devices, automation solutions, thermal management systems, specialty metals, and electrical interconnects; single-use and consumable surgical instruments, implantable components, and drug delivery systems; engineered electrical connectors and electronics packaging to protect sensitive devices and mission-critical electronics; precision motion control products for data storage, medical devices, business equipment, and automation; high-purity powdered metals, strips and foils, specialty clad metals, and metal matrix composites; motor-blower systems and heat exchangers for thermal management, military and commercial aircraft, and military ground vehicles; motors for commercial appliances, food and beverage machines, hydraulic pumps, and industrial blowers; and operates a network of aviation maintenance, repair, and overhaul facilities. AMETEK, Inc. was incorporated in 1930 and is headquartered in Berwyn, Pennsylvania.
Earnings Per Share
As for profitability, AMETEK has a trailing twelve months EPS of $5.67.
PE Ratio
AMETEK has a trailing twelve months price to earnings ratio of 31.69. Meaning, the purchaser of the share is investing $31.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.77%.
Yearly Top and Bottom Value
AMETEK’s stock is valued at $179.71 at 20:22 EST, below its 52-week high of $186.33 and way higher than its 52-week low of $136.89.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 14, 2024, the estimated forward annual dividend rate is 1.12 and the estimated forward annual dividend yield is 0.67%.
Sales Growth
AMETEK’s sales growth is 8.5% for the ongoing quarter and 12.9% for the next.
Moving Average
AMETEK’s value is above its 50-day moving average of $172.89 and above its 200-day moving average of $164.25.
3. ICON plc (ICLR)
6.5% sales growth and 7.55% return on equity
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; and clinical research services, including biostatistics, clinical operations, clinical supplies management, covid-19, data management, decentralized & hybrid clinical solutions, endpoint adjudication services, interactive response technologies, investigator payments, medical affairs, medical writing and publishing, pharmacovigilance, and site and patient solutions. The company also provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. In addition, it offers commercial positioning, early phase, language, medical imaging, and strategic solutions, as well as clinical trial management, consulting, and contract staffing services. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, ICON plc has a trailing twelve months EPS of $8.24.
PE Ratio
ICON plc has a trailing twelve months price to earnings ratio of 39.26. Meaning, the purchaser of the share is investing $39.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.55%.
4. Laureate Education (LAUR)
5.6% sales growth and 15.16% return on equity
Laureate Education, Inc., together with its subsidiaries, offers higher education programs and services to students through a network of universities and higher education institutions. The company provides a range of undergraduate and graduate degree programs in the areas of business and management, medicine and health sciences, and engineering and information technology through campus-based, online, and hybrid programs. It also offers specialized courses for technical and vocational training; and senior high school. Its services are provides in Mexico, Peru, and the United States. The company was formerly known as Sylvan Learning Systems, Inc. and changed its name to Laureate Education, Inc. in May 2004. Laureate Education, Inc. was founded in 1989 and is headquartered in Miami, Florida.
Earnings Per Share
As for profitability, Laureate Education has a trailing twelve months EPS of $0.84.
PE Ratio
Laureate Education has a trailing twelve months price to earnings ratio of 17.5. Meaning, the purchaser of the share is investing $17.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.16%.
5. HealthStream (HSTM)
5.2% sales growth and 5.23% return on equity
HealthStream, Inc. provides Software-as-a-Service (SaaS) based applications for healthcare organizations in the United States. The company's solutions help healthcare organizations in meeting their ongoing clinical development, talent management, training, education, assessment, competency management, safety and compliance, and scheduling, as well as provider credentialing, privileging, and enrollment needs. It offers hStream, a technology platform that powers a range of healthcare workforce solutions. The company provides its solutions to customers across a range of entities within the healthcare industry, including private, not-for-profit, and government entities, as well as pharmaceutical and medical device companies through its direct sales teams. The company was incorporated in 1990 and is headquartered in Nashville, Tennessee.
Earnings Per Share
As for profitability, HealthStream has a trailing twelve months EPS of $0.58.
PE Ratio
HealthStream has a trailing twelve months price to earnings ratio of 47.36. Meaning, the purchaser of the share is investing $47.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.23%.
Yearly Top and Bottom Value
HealthStream’s stock is valued at $27.47 at 20:22 EST, below its 52-week high of $29.12 and way higher than its 52-week low of $20.47.
